R
Reuben M. Cherniack
Researcher at National Jewish Health
Publications - 96
Citations - 10382
Reuben M. Cherniack is an academic researcher from National Jewish Health. The author has contributed to research in topics: Asthma & Lung volumes. The author has an hindex of 42, co-authored 96 publications receiving 9986 citations. Previous affiliations of Reuben M. Cherniack include University of Colorado Denver.
Papers
More filters
Journal Article
Idiopathic Pulmonary Fibrosis
Leslie C. Watters,Marvin I. Schwarz,Reuben M. Cherniack,James A. Waldron,Thaddeus L. Dunn,Ray E. Stanford,Talmadge E. King +6 more
TL;DR: Recent data on the clinical course, therapeutic options, and underlying mechanisms thought to be involved in the pathogenesis of idiopathic pulmonary fibrosis are reviewed.
Journal ArticleDOI
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.
TL;DR: Using these models, clinicians are in a better position to provide prognostic information to patients with IPF and to improve the selection of the most appropriate patients for lung transplantation or other standard or novel therapeutic interventions.
Journal ArticleDOI
A Case Control Etiologic Study of Sarcoidosis: Environmental and Occupational Risk Factors
Lee S. Newman,Cecile S. Rose,Eddy A. Bresnitz,Milton D. Rossman,Juliana Barnard,Margaret Frederick,Michael L. Terrin,Steven E. Weinberger,David R. Moller,Geoffrey McLennan,Gary M. Hunninghake,Louis DePalo,Robert P. Baughman,Michael C. Iannuzzi,Marc A. Judson,Genell L. Knatterud,Bruce Thompson,Alvin S. Teirstein,Henry Yeager,Carol J. Johns,David L. Rabin,Benjamin A. Rybicki,Reuben M. Cherniack +22 more
TL;DR: Several exposures associated with sarcoidosis risk were identified, including insecticides, agricultural employment, and microbial bioaerosols, which were identified in univariable and multivariable analyses.
Journal ArticleDOI
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
Elliot Israel,Vernon M. Chinchilli,Jean G. Ford,Homer A. Boushey,Reuben M. Cherniack,Timothy J. Craig,Aaron Deykin,Joanne K. Fagan,John V. Fahy,James E. Fish,Monica Kraft,Susan J. Kunselman,Stephen C. Lazarus,Robert F. Lemanske,Stephen B. Liggett,Richard J. Martin,Nandita Mitra,Stephen P. Peters,Eric S. Silverman,Christine A. Sorkness,Stanley J. Szefler,Michael E. Wechsler,Scott T. Weiss,Jeffrey M. Drazen +23 more
TL;DR: Genotype at the 16th aminoacid residue of the beta2-adrenergic receptor affects the long-term response to albuterol use and Bronchodilator treatments avoiding albutersol may be appropriate for patients with the Arg/Arg genotype.
Journal ArticleDOI
Idiopathic pulmonary fibrosis: Relationship between histopathologic features and mortality
Talmadge E. King,Marvin I. Schwarz,Kevin K. Brown,Janet A. Tooze,Thomas V. Colby,James A. Waldron,Andrew Flint,W. M. Thurlbeck,Reuben M. Cherniack +8 more
TL;DR: The hypothesis that the critical pathway to end-stage fibrosis is not "alveolitis" but rather the ongoing epithelial damage and repair process associated with persistent fibroblastic proliferation is supported.